Bharat Agri Fert (531862)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 4.45% is positive, showing some operating return before financing effects despite net losses.
• Latest quarter sales of ₹5 Cr indicate the business is still active and generating revenue.
• The stock is at its 52-week high of ₹96.77, reflecting strong market interest and momentum.
• Book value of ₹9.24 per share provides a small tangible asset base, though price is far above it.

Concerns

• Latest quarter net loss of ₹4 Cr and profit growth of -276.70% indicate severe earnings deterioration.
• P/E is effectively nil, and with ROE at -4.27%, equity holders are bearing losses.
• P/B of 10.47 versus book value ₹9.24 leaves no margin of safety at the current price.
• Sales declining at -13.29% and Piotroski F-score of 3/9 point to business and financial stress.

AI Analysis

Let me start with what I do: I search for a wonderful business at a sensible price. Bharat Agri Fert is not that business based on the numbers. The latest quarter shows ₹5 Cr of sales and a ₹4 Cr net loss. Profit growth has collapsed, down 276.70%, while sales are shrinking at 13.29% annually. A negative ROE of -4.27% means shareholders’ capital is earning less than nothing. ROCE of 4.45% is positive, but hardly a strong return on capital employed. Price is ₹96.77, at the very top of the 52-week range, yet book value is only ₹9.24. The market is asking me to pay 10.47 times book value for a loss-making fertilizer company with declining sales. In Graham’s terms, I need a margin of safety. Here I find none. The P/E ratio is meaningless because there are no positive earnings. The Piotroski F-score of 3 out of 9 further warns of weak financial health. There is no dividend, so I am not being paid to wait. FairStock’s 0/100 risk score is consistent with the fundamental damage. Some may call this a turnaround story, pointing to the stock’s rise from ₹20 to ₹96.77. But a rising share price is not a business improvement. Hope is not a strategy. I cannot underwrite a business with negative earnings and negative sales growth at a 10.47 price-to-book ratio. I need evidence of operational recovery: stable quarterly revenue, positive net profit, improving ROE, and credible capital allocation. Until Bharat Agri Fert demonstrates these things, I prefer to watch from the sidelines. The stock may surprise, but preserving capital is my first rule. I would rather miss an exciting rally than participate in an unprofitable enterprise at a speculative price.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer